The 3D Tissue Models Summit will bring together 120+ industry stakeholders across the regulatory, pharma, biotech and academic landscapes to discuss the latest insight into established validation techniques to increase reproducibility and improve the preclinical effectiveness of drug candidates.

Join us and discover:

20+ latest case studies showcasing the advantages of high throughput screening techniques across the 3D model continuum to drive drug discovery progress.

FDA guidance into the regulatory landscape to define a common language of key terms across the industry for end users.

NIH and IQ Consortia discussing the latest developments to incorporate platform-specific standardization and reproducibility metrics for organoids and tissue chip technology.

Model developers and academic experts revealing how to overcome translational challenges to define disease-relevant endpoints across a variety of model types.

Take advantage of this unrivalled learning and networking opportunity packed with content and dedicated interactive formats to ensure you leave equipped with the connections and takeaways to enhance the predictive success of your preclinical 3D models.